ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Teva Pharmaceutical Industries has won FDA approval of Austedo (deutetrabenazine), a deuterated version of tetrabenazine, which was first identified 50 years ago. The drug is intended to treat involuntary writhing movements, or chorea, in peoples with Huntington’s disease. The six deuteriums replace hydrogen and give the molecule a longer lifetime in the body than tetrabenazine does. Both drugs inhibit a vesicular transporter that regulates dopamine in the brain; neither cure the disease (see page 18).
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter